Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Imidazoyl anilide derivatives and methods of use
US10045987B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10045987-B2 |
| Application number | US-201515504134-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 27, 2015 |
| Priority date | Aug 28, 2014 |
| Publication date | Aug 14, 2018 |
| Grant date | Aug 14, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides kinase inhibitor analogs with improved properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the present invention provides nilotinib analogs that provide therapeutic benefits.
First claim
Opening claim text (preview).
We claim: 1. A composition comprising the compound of Formula I, wherein R 1 is an hydroxyl, and R 2 , is an alkyl, each optionally substituted, or a salt thereof. 2. The composition of claim 1 , wherein said composition is suitable for administration to an animal. 3. The composition of claim 2 , wherein said animal is a human.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
Saturated compounds having only one carboxyl group and containing keto groups · CPC title
with hetero atoms directly attached to ring carbon atoms · CPC title
having two double bonds between ring members or between ring members and non-ring members · CPC title
- A61K31/506Primary
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10045987B2 cover?
- The present invention provides kinase inhibitor analogs with improved properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the present invention provides nilotinib analogs that provide therapeutic benefits.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/506. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).